Nyrada Inc (ASX: NYR) is set to commence site initiation visits for its Nyrada PROTECT-MI Phase IIa trial in March 2026, with first patient dosing expected in April 2026. The trial will assess Xolatryp for myocardial ischemia reperfusion injury in STEMI heart attack patients, targeting a condition with no approved therapies.
Nyrada prepares to dose first heart attack patients in landmark Phase IIa trial
Nyrada has confirmed that seven hospitals across five Australian states and territories will serve as initial sites for the Nyrada PROTECT-MI Phase IIa trial, which stands for Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction. The study is designed to enrol 100 evaluable patients (50 receiving drug, 50 receiving placebo) suffering from STEMI heart attacks undergoing percutaneous coronary intervention.
STEMI heart attacks represent a severe, life-threatening event caused by complete blockage of a major coronary artery, stopping blood flow to a portion of the heart muscle. Currently, no therapies have been approved to specifically target cardiac ischemia reperfusion injury, which plays a major role in causing long-term heart damage following an acute myocardial infarction.
Drug manufacture under Good Manufacturing Process has been completed, with delivery to the central distribution depot expected in the last week of March 2026. Formal GMP documentation is expected to follow shortly thereafter, allowing patient recruitment to commence in April 2026. The company will update the market once the first patient has been dosed.
For investors, the commencement of this Phase IIa trial represents a significant clinical milestone. Xolatryp is positioned to address a major treatment gap in a patient population with zero approved therapeutic options for this specific injury mechanism, potentially establishing first-mover advantage in a substantial unmet medical need.
When big ASX news breaks, our subscribers know first
What is ischemia reperfusion injury and why does it matter?
During a STEMI heart attack, a complete blockage of a coronary artery cuts off blood supply to heart tissue, causing damage from oxygen deprivation. The standard emergency treatment involves rapidly restoring blood flow through procedures such as angioplasty with stenting.
However, the restoration of blood flow itself triggers a secondary injury process known as ischemia reperfusion injury. This represents a clinical paradox where the very intervention needed to save the heart muscle causes additional cellular damage. The influx of oxygen and nutrients after a period of deprivation generates harmful reactive oxygen species and triggers pathological calcium entry into cells, leading to mitochondrial dysfunction and further tissue death.
Current standard of care addresses the initial blockage but offers no specific treatment for this secondary injury phase. Every patient undergoing percutaneous coronary intervention for STEMI remains vulnerable to this additional damage, which contributes to long-term cardiac impairment.
Xolatryp works by inhibiting TRPC 3/6/7 ion channels, limiting pathological calcium influx into cells during the reperfusion phase. By reducing calcium overload, the therapy aims to protect mitochondrial function and minimise the extent of injury that occurs when blood flow is restored. A completed Phase I clinical trial has already assessed safety, tolerability, and pharmacokinetics of the compound.
From an investment perspective, successful treatment of ischemia reperfusion injury represents a significant commercial opportunity. Every STEMI patient undergoing primary percutaneous coronary intervention globally represents a potential treatment candidate, addressing a market with substantial scale and no competing approved therapies.
How Xolatryp works at the cellular level
Xolatryp is a small molecule therapy that inhibits calcium ion influx via TRPC 3/6/7 channels. When ischemia reperfusion occurs, excessive calcium enters cardiac cells through these channels, overwhelming cellular defences and damaging the mitochondria that power cellular function.
By blocking these specific ion channels, Xolatryp limits the pathological calcium entry that drives secondary injury. This mechanism helps preserve mitochondrial function during the critical reperfusion window, potentially reducing the overall extent of cardiac tissue damage.
In the PROTECT-MI trial, patients will receive a 3 mg/kg intravenous infusion over 6 hours. The dosing regimen and safety profile are informed by the completed Phase I trial, which established preliminary pharmacokinetic and tolerability data in healthy volunteers.
Seven major Australian hospitals to participate in PROTECT-MI
The Nyrada PROTECT-MI Phase IIa trial will be conducted across seven hospitals spanning five states and territories, demonstrating broad institutional support and geographic diversity. Professor William Chan has been confirmed as Coordinating Principal Investigator.
The selected sites include:
- Victoria: Sunshine Hospital, Northern Health Hospital
- New South Wales: Nepean Hospital, Liverpool Hospital
- South Australia: Royal Adelaide Hospital
- Western Australia: Sir Charles Gairdner Hospital
- Tasmania: Royal Hobart Hospital
This multi-site, multi-state design demonstrates operational readiness and clinical infrastructure to execute patient recruitment efficiently across major metropolitan centres. The involvement of established cardiac centres with high STEMI patient volumes positions the trial to complete enrolment within a reasonable timeframe.
For investors, the calibre and geographic spread of participating institutions signals strong clinical community engagement with the programme and supports the feasibility of the recruitment timeline.
Trial design and key endpoints
The PROTECT-MI study is a prospective, randomised, double-blind, placebo-controlled, multi-centre trial. The primary objective is to evaluate the safety and tolerability of Xolatryp when delivered as an infusion in patients presenting with acute STEMI undergoing primary percutaneous coronary intervention.
Secondary endpoints include assessment of cardiac infarct size using cardiac MRI in participants with pre-percutaneous coronary intervention TIMI 0 or 1 flow, incidence of arrhythmias of interest, blood pharmacokinetics, relative difference in serum levels of Troponin I, and patient-reported outcomes at Day 30.
| Trial Element | Detail |
|---|---|
| Design | Double-blind, placebo-controlled, randomised, multi-centre |
| Patients | 100 evaluable (50 drug, 50 placebo) |
| Dosing | 3 mg/kg IV infusion over 6 hours |
| Primary endpoint | Safety and tolerability |
| Key secondary | Cardiac infarct size via MRI |
The study will remain blinded until completion, meaning efficacy data will only be analysed once all patients have completed the protocol. Nyrada will provide regular updates on participant recruitment and Safety Review Committee assessments throughout the trial period.
The next major ASX story will hit our subscribers first
US regulatory pathway advances with IND preparation
Nyrada has commenced preparation of its Investigational New Drug application for submission to the US Food and Drug Administration. This parallel regulatory initiative positions the company to pursue clinical development in the world’s largest pharmaceutical market alongside the Australian Phase IIa programme.
The IND submission process involves compiling comprehensive preclinical and clinical data to support the safety of proceeding with human trials under FDA oversight. Successful IND clearance would enable Nyrada to conduct future clinical studies in US centres, potentially accelerating development timelines and expanding the patient recruitment base for subsequent trial phases.
For investors, this forward-looking regulatory strategy signals management’s intent to pursue global market access rather than limiting development to Australian approval pathways alone. US market entry represents a substantial value driver for biotechnology companies, given the size of the cardiac care market and premium pricing environment.
What comes next for Nyrada
The near-term catalyst timeline provides multiple potential share price triggers over the coming months:
- Site initiation visits commence in March 2026
- GMP drug delivery to central depot in the last week of March 2026
- Patient recruitment commences in April 2026
- First patient dosing in April 2026
- IND submission preparation ongoing
Nyrada will update the market once the first patient has been dosed in the PROTECT-MI trial. The company will provide regular updates on participant recruitment progress and any Safety Review Committee assessments conducted during the blinded study period.
Efficacy data will only become available after study completion, when the trial is unblinded and final analysis is performed. This means investors should anticipate a period of operational updates focused on recruitment milestones and safety monitoring rather than preliminary efficacy signals.
Nyrada Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical ion channels.
The broader Nyrada pipeline includes potential applications of TRPC channel inhibition beyond cardioprotection, with preclinical studies demonstrating neuroprotection effects in traumatic brain injury and stroke models. The PROTECT-MI Phase IIa trial represents a pivotal value inflection point for the lead programme, with successful safety and preliminary efficacy data potentially supporting advancement to larger-scale efficacy trials and expanded regulatory filings.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX news within minutes of release, complete with in-depth analysis. Get alerts on companies like Nyrada the moment market-moving announcements drop. Click the “Free Alerts” button at Big News Blast to stay ahead on healthcare and biotech developments.